UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.213

Sortiert nach

Production Planning with Capacitated Resources and Congestion

1st ed. 2020., 2020

Volltextzugriff (PDF)

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis

The European respiratory journal, 2011-07, Vol.38 (1), p.59-69

2011

Volltextzugriff (PDF)

Membrane-bound progesterone receptors in the canine uterus and placenta; possible targets in the maintenance of pregnancy

Theriogenology, 2023-10, Vol.210, p.68-83

2023

Volltextzugriff (PDF)

T.P.5

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.861-861

2014

Volltextzugriff (PDF)

G.P.106

Neuromuscular disorders : NMD, 2014-10, Vol.24 (9), p.826-827

2014

Volltextzugriff (PDF)

First drug registry in Duchenne muscular dystrophy (DMD) to assess Translarna (Ataluren) use, safety, and effectiveness in routine clinical practice

Neuromuscular disorders : NMD, 2015-10, Vol.25, p.S259-S259

2015

Volltextzugriff (PDF)

Are effects of Translarna (Ataluren) on muscle strength more discernible in younger patients with Duchenne muscular dystrophy (DMD)?

Neuromuscular disorders : NMD, 2015-10, Vol.25, p.S264-S264

2015

Volltextzugriff (PDF)

S1 Development of a confirmatory phase 3, multicentre, randomized, double-blind, placebo-controlled study of ataluren in patients with nonsense mutation Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2014-03, Vol.24, p.S31-S31

2014

Volltextzugriff (PDF)

P159 – 2412: First drug registry in Duchenne muscular dystrophy (DMD) to assess Translarna use, safety, and effectiveness in routine clinical practice

European journal of paediatric neurology, 2015-05, Vol.19, p.S138-S138

2015

Volltextzugriff (PDF)

P.11.18 Design of a confirmatory phase 3, multicenter, randomized, double-blind, placebo-controlled study of ataluren in patients with nonsense mutation Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.804-804

2013

Volltextzugriff (PDF)

P.11.19 Phase 2b, dose-ranging study of ataluren (PTC124®) innonsense mutation Duchenne muscular dystrophy – results of a post hoc analysis of change in %-predicted 6-min walk distance

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.804-804

2013

Volltextzugriff (PDF)

166. Improvements in muscle function and accidental falling in ataluren-treated patients with nonsense mutation dystrophinopathy (Duchenne/Becker muscular dystrophy)

Clinical neurophysiology, 2012-06, Vol.123 (6), p.e64-e64

2012

Volltextzugriff (PDF)

Importance of Health Policy and Systems Research for Strengthening Rehabilitation in Health Systems: A Call to Action to Accelerate Progress

Advances in rehabilitation science and practice, 2023-01, Vol.12, p.27536351231214307-27536351231214307

2023

Volltextzugriff (PDF)

165. Development and validation of the 6-min walk test as a clinical endpoint in Duchenne and Becker muscular dystrophy

Clinical neurophysiology, 2012-06, Vol.123 (6), p.e64-e64

2012

Volltextzugriff (PDF)

THE 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study

Muscle & nerve, 2013-09, Vol.48 (3), p.343-356

2013

Volltextzugriff (PDF)

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study

Muscle & nerve, 2013-09, Vol.48 (3), p.357-368

2013

Volltextzugriff (PDF)

P.2.8 The 6-min walk test and clinical endpoints in Duchenne MD: Reliability, validity, and clinically-important differences

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.751-751

2013

Volltextzugriff (PDF)

P.2.9 The 6-min walk test and other endpoints in Duchenne MD: Multi center longitudinal natural history observations over 48 weeks

Neuromuscular disorders : NMD, 2013-10, Vol.23 (9), p.751-751

2013

Volltextzugriff (PDF)

P1.33 Disease progression observed in clinical outcome measures in placebo-treated patients with nonsense mutation dystrophinopathy

Neuromuscular disorders : NMD, 2011-10, Vol.21 (9), p.651-651

2011

Volltextzugriff (PDF)

Evaluation of malnutrition development risk in hospitalized children

Nutrition (Burbank, Los Angeles County, Calif.), 2018-04, Vol.48, p.40-47

2018

Volltextzugriff (PDF)

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2016-09, Vol.26 (9), p.576-583

2016

Volltextzugriff (PDF)

Corticosteroids in Duchenne muscular dystrophy: Major variations in practice

Muscle & nerve, 2013-07, Vol.48 (1), p.27-31

2013

Volltextzugriff (PDF)

Nutritional characteristic of children with inflammatory bowel disease in the nationwide inflammatory bowel disease registry from the Mediterranean region

European journal of clinical nutrition, 2022-09, Vol.76 (9), p.1289-1296

2022

Volltextzugriff (PDF)

Application of Microarray-Based Comparative Genomic Hybridization in Prenatal and Postnatal Settings: Three Case Reports

Genetics Research International, 2011-01, Vol.2011, p.976398-9

2011

Volltextzugriff (PDF)

P3.51 Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD)

Neuromuscular disorders : NMD, 2010-10, Vol.20 (9), p.656-657

2010

Volltextzugriff (PDF)

1 – 25 von 2.213

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.694)
Mit Volltextzugriff
(2.023)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.304)
Life Sciences & Biomedicine
(894)
Humans
(570)
Male
(383)
Female
(374)
Technology
(366)
Surgery
(221)
Adult
(217)
Biological And Medical Sciences
(209)
Middle Aged
(192)
Animals
(178)
Operations Research & Management Science
(178)
Engineering
(168)
Medical Sciences
(167)
Physical Sciences
(146)
Neurosciences & Neurology
(135)
Social Sciences
(130)
Adolescent
(129)
Computer Science
(122)
Business & Economics
(119)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(37)

Menü

Weitere Dienste

Einstellungen

Production Planning with Capacitated Resources and Congestion

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis

Membrane-bound progesterone receptors in the canine uterus and placenta; possible targets in the maintenance of pregnancy

T.P.5

G.P.106

First drug registry in Duchenne muscular dystrophy (DMD) to assess Translarna (Ataluren) use, safety, and effectiveness in routine clinical practice

Are effects of Translarna (Ataluren) on muscle strength more discernible in younger patients with Duchenne muscular dystrophy (DMD)?

S1 Development of a confirmatory phase 3, multicentre, randomized, double-blind, placebo-controlled study of ataluren in patients with nonsense mutation Duchenne muscular dystrophy

P159 – 2412: First drug registry in Duchenne muscular dystrophy (DMD) to assess Translarna use, safety, and effectiveness in routine clinical practice

P.11.18 Design of a confirmatory phase 3, multicenter, randomized, double-blind, placebo-controlled study of ataluren in patients with nonsense mutation Duchenne muscular dystrophy

P.11.19 Phase 2b, dose-ranging study of ataluren (PTC124®) innonsense mutation Duchenne muscular dystrophy – results of a post hoc analysis of change in %-predicted 6-min walk distance

166. Improvements in muscle function and accidental falling in ataluren-treated patients with nonsense mutation dystrophinopathy (Duchenne/Becker muscular dystrophy)

Importance of Health Policy and Systems Research for Strengthening Rehabilitation in Health Systems: A Call to Action to Accelerate Progress

165. Development and validation of the 6-min walk test as a clinical endpoint in Duchenne and Becker muscular dystrophy

THE 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study

P.2.8 The 6-min walk test and clinical endpoints in Duchenne MD: Reliability, validity, and clinically-important differences

P.2.9 The 6-min walk test and other endpoints in Duchenne MD: Multi center longitudinal natural history observations over 48 weeks

P1.33 Disease progression observed in clinical outcome measures in placebo-treated patients with nonsense mutation dystrophinopathy

Evaluation of malnutrition development risk in hospitalized children

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy

Corticosteroids in Duchenne muscular dystrophy: Major variations in practice

Nutritional characteristic of children with inflammatory bowel disease in the nationwide inflammatory bowel disease registry from the Mediterranean region

Application of Microarray-Based Comparative Genomic Hybridization in Prenatal and Postnatal Settings: Three Case Reports

P3.51 Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD)

Suchergebnisse filtern